QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other ...
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding ...
12.1% of patients on atogepant discontinued due to side effects vs. 29.6% on topiramate. 64.1% of atogepant users saw migraine days cut by half, compared to 39.3% for topiramate. The market’s back, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback